St Jude's bipolar lead for CRT (cardiac resynchronisation therapy) devices:
This article was originally published in Clinica
The US FDA has given St Jude Medical the all-clear to sell its QuickSite 1056T bipolar lead, a product designed for use with the company's Epic and Atlas cardiac resynchronisation therapy (CRT) devices for treating heart failure. "The bipolar lead leverages the clinically proven design of the QuickSite unipolar lead, adding the flexibility of bipolar pacing to better manage patients with phrenic nerve stimulation," said Michael Coyle, president of the St Paul, Minnesota firm's cardiac rhythm management division. The product is scheduled for launch in May 2005.
You may also be interested in...
Pharma manufacturing is operating well below normal levels in India, disrupted by labor absenteeism and supply chain issues amid the ongoing lock-down in the country, though the government is actively engaged in addressing bottlenecks. A speedy recovery is vital not just for domestic supplies.
Moderna is pursuing a single-antigen strategy even though some of its mRNA vaccines have included multiple antigens; the SARS-CoV-2 spike protein likely provides the best antigen for developing immunity against the virus.
Latest warnings also include second and third businesses in US cannabidiol and hemp sector found making unlawful claims for treating and preventing COVID-19. Four of five firms warned apparently responded by removing violative claims from websites and social media posts.